Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
暂无分享,去创建一个
William D Rooney | W. Rooney | E. Neuwelt | L. Muldoon | B. Hamilton | C. Varallyay | Ahmed M Raslan | Marianne Haluska | Seymur Gahramanov | Leslie L Muldoon | Edward A Neuwelt | J. M. Njus | Bronwyn E Hamilton | A. Raslan | Csanad G Varallyay | Jeffrey M Njus | S. Gahramanov | M. Haluska | Ahmed M. Raslan | Bronwyn E. Hamilton | William D. Rooney | Marianne Haluska | William D Rooney
[1] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[2] J E Heiserman,et al. Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.
[3] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[4] A. Brandes,et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.
[5] Yue Cao,et al. Clinical investigation survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT , 2006 .
[6] M Takahashi,et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.
[7] A Gregory Sorensen,et al. Perfusion MR imaging: moving forward. , 2008, Radiology.
[8] G. van Kaick,et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy , 2002, Neuroradiology.
[9] J. Fike,et al. The Radioresponse of the Central Nervous System: A Dynamic Process , 2000, Radiation research.
[10] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[11] M. Pintilie,et al. Hypoxia and Hypoxia-Inducible Factor-1 Target Genes in Central Nervous System Radiation Injury , 2004, Clinical Cancer Research.
[12] G Johnson,et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.
[13] Michael H Lev,et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.
[14] Ying Lu,et al. Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume , 2004, Journal of magnetic resonance imaging : JMRI.
[15] M. Morino,et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery —In malignant glioma— , 2004, Annals of nuclear medicine.
[16] W. Koch,et al. Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas , 2005, Neurosurgery.
[17] A. Brandes,et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Yue Cao,et al. Physiologic and metabolic magnetic resonance imaging in gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P Bachert,et al. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. , 2001, AJNR. American journal of neuroradiology.
[20] Michael Jerosch-Herold,et al. THE POTENTIAL OF FERUMOXYTOL NANOPARTICLE MAGNETIC RESONANCE IMAGING, PERFUSION, AND ANGIOGRAPHY IN CENTRAL NERVOUS SYSTEM MALIGNANCY: A PILOT STUDY , 2007, Neurosurgery.
[21] Andrew E. Sloan,et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.
[22] R. Salem,et al. Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer , 2007, Annals of Surgical Oncology.
[23] A. J. van der Kogel,et al. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. , 2004, Molecular interventions.
[24] K. Schmainda,et al. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.
[25] A. Waldman,et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? , 2008, Radiology.
[26] Xin Li,et al. Dynamic MRI Using Iron Oxide Nanoparticles to Assess Early Vascular Effects of Antiangiogenic versus Corticosteroid Treatment in a Glioma Model , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] D. Knol,et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence , 2009, Journal of Neurology.
[28] E F Halpern,et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.
[29] M. Berger,et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2009, Radiology.
[30] Bart Neyns,et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.